# Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

> **NCT00529516** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1252 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluarix
- **BIOLOGICAL:** GSK Biologicals Influenza Vaccine GSK576389A

## Key facts

- **NCT ID:** NCT00529516
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-15
- **Primary completion:** 2007-12-21
- **Final completion:** 2008-06-04
- **Target enrollment:** 1252 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529516, "Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00529516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*